Top
Summary
All studies
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
Peer-reviewed
All outcomes

Feedback
Analgesics⏵
Antiandrogens⏵
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
Top
All BMS mAbs studies
 
Feedback
Home
c19early.org COVID-19 treatment researchBMS mAbsBMS mAbs (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis

Outcomes in COVID-19 BMS mAbs studies

Home
Post
Share
@CovidAnalysis
StudiesStudies
FeedbackFeedback
All studies   Hospitalization   Serious outcomes   Recovery   Viral clearance   RCTs   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -36% 1 210 Improvement, Studies, Patients Relative Risk Hospitalization -36% 1 210 Viral clearance 4% 1 210 RCTs -36% 1 210 Early -36% 1 210 BMS mAbs for COVID-19 c19early.org June 2024 FavorsBMS mAbs Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Corada (DB RCT) -36% 1.36 [0.31-5.92] hosp. 4/104 3/106 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.7 Early treatment -36% 1.36 [0.31-5.92] 4/104 3/106 36% higher risk All studies -36% 1.36 [0.31-5.92] 4/104 3/106 36% higher risk 1 BMS mAbs COVID-19 study c19early.org June 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.7 Effect extraction pre-specified(most serious outcome) Favors BMS mAbs Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Corada (DB RCT) -36% 1.36 [0.31-5.92] hosp. 4/104 3/106 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.7 Early treatment -36% 1.36 [0.31-5.92] 4/104 3/106 36% higher risk All studies -36% 1.36 [0.31-5.92] 4/104 3/106 36% higher risk 1 BMS mAbs COVID-19 hospitalization result c19early.org June 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.7 Favors BMS mAbs Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Corada (DB RCT) -36% 1.36 [0.31-5.92] hosp. 4/104 3/106 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.7 Early treatment -36% 1.36 [0.31-5.92] 4/104 3/106 36% higher risk All studies -36% 1.36 [0.31-5.92] 4/104 3/106 36% higher risk 1 BMS mAbs COVID-19 serious outcome c19early.org June 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.7 Effect extraction pre-specified(most serious outcome) Favors BMS mAbs Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Corada (DB RCT) 20% 0.80 [0.57-1.12] recov. time 105 (n) 106 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.19 Early treatment 20% 0.80 [0.57-1.12] 105 (n) 106 (n) 20% lower risk All studies 20% 0.80 [0.57-1.12] 105 (n) 106 (n) 20% lower risk 1 BMS mAbs COVID-19 recovery result c19early.org June 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.19 Favors BMS mAbs Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Corada (DB RCT) 4% 0.96 [0.87-1.06] viral+ 104 (n) 106 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.45 Early treatment 4% 0.96 [0.87-1.06] 104 (n) 106 (n) 4% lower risk All studies 4% 0.96 [0.87-1.06] 104 (n) 106 (n) 4% lower risk 1 BMS mAbs COVID-19 viral clearance result c19early.org June 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.45 Favors BMS mAbs Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Corada (DB RCT) -36% 1.36 [0.31-5.92] hosp. 4/104 3/106 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.7 Early treatment -36% 1.36 [0.31-5.92] 4/104 3/106 36% higher risk All studies -36% 1.36 [0.31-5.92] 4/104 3/106 36% higher risk 1 BMS mAbs COVID-19 Randomized Controlled Trials c19early.org June 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.7 Effect extraction pre-specified(most serious outcome) Favors BMS mAbs Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Corada (DB RCT) -36% 1.36 [0.31-5.92] hosp. 4/104 3/106 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.7 Early treatment -36% 1.36 [0.31-5.92] 4/104 3/106 36% higher risk All studies -36% 1.36 [0.31-5.92] 4/104 3/106 36% higher risk 1 BMS mAbs COVID-19 peer reviewed studies c19early.org June 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.7 Effect extraction pre-specified(most serious outcome) Favors BMS mAbs Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Corada (DB RCT) -36% 1.36 [0.31-5.92] hosp. 4/104 3/106 Improvement, RR [CI] Treatment Control Corada (DB RCT) 17% 0.83 [0.70-0.98] progression 104 (n) 106 (n) Corada (DB RCT) 20% 0.80 [0.57-1.12] recov. time 105 (n) 106 (n) Corada (DB RCT) 4% 0.96 [0.87-1.06] viral+ 104 (n) 106 (n) Corada (DB RCT) 0% 1.00 [0.89-1.11] viral+ 104 (n) 106 (n) Corada (DB RCT) 3% 0.97 [0.76-1.25] viral+ 104 (n) 106 (n) BMS mAbs COVID-19 outcomes c19early.org June 2024 Favors BMS mAbs Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0